

Associate, Boston

Mergers and Acquisitions



T: 617.573.4819
marissa.leonce@skadden.com

Education

J.D., Harvard Law School, 2016
M.S., University of North Texas, 2012
B.A., Texas A & M University, 2007

Bar Admissions

Massachusetts

Marissa Leonce represents clients in mergers, acquisitions and other transactions. She also advises clients on shareholder activism defense, corporate governance and other general corporate matters.

Ms. Leonce's significant representations include:

- Alcon in its \$753 million acquisition of Aerie Pharmaceuticals;
- Antares Pharma in its sale to Halozyme for \$1 billion;
- Dicerna Pharmaceuticals in its sale to Novo Nordisk for \$3.3 billion;
- MorphoSys in its \$1.7 billion acquisition of Constellation Pharmaceuticals and its related financing from Royalty Pharma totaling over \$2 billion;
- WeWork in its merger with BowX Acquisition Corp., a special purpose acquisition company, as a result of which WeWork would become a public company with an implied initial enterprise value of \$9 billion;
- Boston Dynamics in its sale to Hyundai Motor Group for \$1.1 billion;
- CerSci Therapeutics in its sale to ACADIA Pharmaceuticals for up to \$939.5 million;
- Stemline Therapeutics in its sale to Menarini Group for up to \$677 million;
- ArQule in its sale to Merck for \$2.7 billion;
- Alder in its sale to Lundbeck for up to \$1.95 billion;
- Clementia Pharmaceuticals in its sale to Ipsen for up to \$1.31 billion;
- Carbonite in its \$618.5 million acquisition of Webroot;
- United Natural Foods in its acquisition of SUPERVALU for \$2.9 billion, including assumption of outstanding debt and liabilities;
- Hasbro in its \$522 million acquisition of Saban Brands' Power Rangers and other entertainment assets;
- Ultragenyx Pharmaceutical in its successful topping bid for Dimension Therapeutics;
- Merrimack Pharmaceuticals in its asset sale to Ipsen for up to \$1.025 billion; and
- Intralinks Holdings, Inc., a leading global technology provider of secure enterprise content collaboration solutions, in its \$820 million acquisition by Synchronoss Technologies, Inc.